Keyword: Celgene

Another week, another dismal pharma trust and reputation poll. This time, the poll comes from the Reputation Institute.

Blockbusters Humira and Keytruda will lead 2024 sales, according to an EvaluatePharma report, joined by new Sanofi launch Dupixent.

Amid an industrywide probe, Lundbeck reached a tentative settlement wrapping up its own copay charity allegations.

Pharma authorized tens of billions of dollars' worth of share buybacks before or shortly after tax reform, and that irked an industry veteran.

Embattled Celgene already bid goodbye to its COO and business development guru, and now it's moving up its executive ranks to make more changes.

Looks like Merck’s Keytruda could get some company in the lung cancer chemo-combo department.

The list the FDA published last week is not likely to cause broader damage to the reputations of companies named, experts say.

After pharma suffered an unexpected loss in this year's budget deal, the industry sees an opportunity to get some relief.

Celgene's business development chief George Golumbeski left the company in April as Celgene struggles to recover from months of setbacks.

FDA Commissioner Scott Gottlieb has turned to an unusual tactic to tackle drug pricing through generics competition.